Objective: To report the incidence, risk factors, and treatments of renal subcapsular hemorrhage (RSH) complicating ureteroscopic lithotripsy (URSL). Patients and Methods: Data from 1,918 URSLs performed between January 2004 and March 2012 were retrospectively analyzed. Patients' data included age, sex, relevant medical history, stone side, size, and degree of hydronephrosis. Results: All 8 patients were identified as having an RSH after URSL. There were 2 males and 6 females with a mean age of 45.6 years (range 30-62 years). The patients' relevant medical histories (renal calculi extracorporeal shock wave lithotripsy, renal operation and hypertension) were statistically different between those who did and did not develop an RSH. Acute onset of flank pain is the most common symptom. Three patients with infective and large hemorrhage were managed by percutaneous nephrostomy in 1 and percutaneous subcapsular drainage in 2. Five patients with small and uninfected hemorrhage were managed conservatively. Conclusions: The rate of development of RSH complicating URSL is very low. RSH complicating URSL can occur in patients with underlying renal abnormalities. RSH is rarely associated with abrupt hemodynamic instability and usually not lethal. Treatment is selected based on the patient's hemodynamic state, infection, renal function, and the feasibility of treatment modality.

Keywords:
Renal subcapsular hemorrhage, Ureteroscopic lithotripsy, Percutaneous drain
1.
Pérez-Castro Ellendt E, Martínez-Piñeiro JA: Ureteral and renal endoscopy. A new-approach. Eur Urol 1982;8:117-120.
2.
Schultz A, Kristensen JK, Bilde T, Eldrup J: Ureteroscopy: results and complications. J Urol 1987;137:865-866.
3.
Blute ML, Segura JW, Patterson DE: Ureteroscopy. J Urol 1988;139:510-512.
4.
D'Addessi A, Bassi P: Ureterorenoscopy: avoiding and managing the complications. Urol Int 2011;87:251-259.
5.
Bansal U, Sawant A, Dhabalia J: Subcapsular renal hematoma after ureterorenoscopy: an unknown complication of a known procedure. Urol Ann 2010;2:119-121.
6.
Bai J, Li C, Wang S, Liu J, Ye Z, Yu X, Xi Q, Ni M, He D: Subcapsular renal haematoma after holmium:yttrium-aluminum-garnet laser reterolithotripsy. BJU Int 2012;109:1230-1234.
7.
Navarro HP, Lopez PC, Ruiz JM: Renal hematoma after extracorporeal shock-wave lithotripsy (ESWL). Actas Urol Esp 2009;33:296-303.
8.
Xia D, Chen SW, Zhang HK, Wang S: Renal subcapsular haematoma: an unusual complication of renal artery stenting. Chin Med J (Engl) 2011;124:1438-1440.
9.
Hsin CY, Jung TS, Wen JW: Spontaneous bilateral subcapsular hematoma of the kidneys: a case report. J Taiwan Urol Assoc 2008;19:228-231.
10.
Bach C, Nesar S, Kumar P, Goyal A, Kachrilas S, Papatsoris A, Masood J, Buchholz N: The new digital flexible ureteroscopes: ‘size does matter' - increased ureteric access sheath use! Urol Int 2012;89:408-411.
11.
Duchene DA, Williams RD, Winfield HN: Laparoscopic management of bilateral page kidneys. Urology 2007;69:1208.e1-e3.
12.
Gupta NP, Karan SC, Aron M, Pawar R, Ansari MS: Spontaneous perirenal haematoma: a case report and review of literature. Urol Int 2000;64:213-215.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.